Study of adebrelimab plus famitinib and chemo before surgery for esophageal cancer
Part of Cancer, Digestive system clinical trials.
This trial tests a combination of an immunotherapy drug (adebrelimab) and a targeted therapy (famitinib) with chemotherapy before surgery for esophageal cancer. The goal is to see if this approach can shrink the tumor and improve surgical outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have esophageal squamous cell carcinoma confirmed by biopsy.
- Your cancer must be at a specific stage (cT1b-2N+ or cT3-4a, any N) that has not spread to distant organs.
- You must not have received any prior treatment for this cancer.
- You must be between 18 and 75 years old.
- You must be in good overall health with adequate blood, liver, and kidney function.
- You must be willing to undergo surgery after the study treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding a new immunotherapy drug (adebrelimab) to standard chemotherapy, given before surgery, helps shrink esophageal cancer tumors and improves outcomes. It is for people with a specific type of esophageal cancer that has not spread widely.
This trial tests a drug called Adebrelimab combined with chemotherapy before surgery for esophageal cancer. It aims to shrink the tumor and make it easier to remove completely.
This trial tests a combination of immunotherapy (adebrelimab) and two chemotherapy drugs before surgery for patients with advanced but removable esophageal cancer. The goal is to see if this treatment shrinks the tumor and improves outcomes.
This trial tests a combination of two targeted drugs (nimotuzumab and camrelizumab) plus standard chemotherapy before surgery for people with esophageal squamous cell carcinoma. The goal is to see if this approach helps shrink the tumor and improve outcomes.
This trial tests a new immunotherapy drug (Envafolimab) combined with standard chemotherapy before surgery for esophageal cancer that has not spread far. The goal is to see if this combination can shrink tumors and improve outcomes.
This trial tests a drug called adebrelimab (an immunotherapy) combined with chemotherapy and radiation for people with advanced esophageal cancer that cannot be removed by surgery or has come back after surgery. It aims to see if the combination is safe and effective.
Hear when a new Esophageal Squamous Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.